Biological Activity
PF-05231023, a long-acting fibroblast growth factor 21 (FGF21) analog, is a FGF21-receptor agonist, suitable for development as a potential treatment for T2DM[1][5].
In Vitro
PF-05231023 is a long-acting fibroblast growth factor 21 (FGF21) analog[2].
In Vivo
Administration of native FGF21 and PF-05231023 ( 3 mg/kg or 10 mg/kg ) improves glucose tolerance and liver insulin sensitivity in Zucker rats[3]. PF-05231023 (10 mg/kg) shows protective effects on Akita retinas. PF-05231023 (10 mg/kg) decreases retinal inflammation in diabetic mice. PF-05231023 (10 mg/kg) administration reduces retinal IL-1β mRNA expression in Akita mice. PF-05231023 (10 mg/kg) administration increases cone-specific arrestin4 expression in Akita mice. PF-05231023 (10 mg/kg) administration restores photoreceptor morphology in Akita mice. PF-05231023 (10 mg/kg) inhibits oxidative-stress-induced inflammation in photoreceptors. PF-05231023 (10 mg/kg) administration decreases the variability of retinal NRF2 levels and shows a trend (non-significant) towards increased NRF2 levels in Akita mice[4].
References & source
Published experimental findings depend on the model and assay conditions. They do not guarantee equivalent performance in every application. For laboratory research use only.
